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Background: While the impact of volatile anaesthetics to induce malignant hyperthermia (MH) is abundantly
clear, the role of succinylcholine still remains controversial. To evaluate the influence of succinylcholine on porcine
MH events, the authors investigated the hemodynamic and metabolic responses in MH susceptible (MHS) and
non-susceptible (MHN) swine following either succinylcholine or halothane application alone or a combination of
both substances.
Methods: With approval of the local animal care committee 27 MHS and 30 MHN pigs were anaesthetized and
mechanically ventilated. Fiberoptic probes for continuous PCO2 measurement were inserted into the femoral vein
and the triceps muscle. Group A received succinylcholine 4 mg/kg, group B incremental doses of halothane (0.5,
1.0 vol%) and group C succinylcholine and halothane simultaneously. Vital signs were recorded continuously.
Results: Prior to drug application measured values did not differ between MHS and MHN. While MHN pigs did not
show relevant alterations, succinylcholine, halothane and the combination of both lead to significant hemodynamic
and metabolic changes in MHS swine.
Conclusions: Hemodynamic and metabolic alterations following succinylcholine were similar to halothane in MHS
pigs. The combination of both pharmacological agents potentiated the observed effects. According to these results
succinylcholine acted as an independent and supportive factor during onset of an MH episode.
Keywords: Malignant hyperthermia, Succinylcholine, Halothane, SwineBackground
Malignant hyperthermia (MH) is a potentially lethal
pharmacogenetic disorder characterized by a disturbance
of skeletal muscle calcium homeostasis. In predisposed
humans and animals exposure to triggering agents may
lead to a hypermetabolic muscular syndrome. Uncon-
trolled sarcoplasmic calcium release caused by mutations
in the ryanodine receptor subtype 1 or in the dihydrophyr-
idine receptor results in hypoxemia, hypercapnia, tachy-
cardia, muscular rigidity, acidosis, hyperkalaemia and
hyperthermia [1]. While the impact of volatile anaesthetics
in the development of MH is abundantly clear, the role of
the depolarising muscle relaxant succinylcholine (SCh)
still remains controversial [2]. For instance, application* Correspondence: schuster_f@ukw.de
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unless otherwise stated.of commonly used halogenated anaesthetics induces
pathological muscular contractions in muscle bundles
of susceptible patients in vitro [3], whereas SCh did not
induce a reproducible muscular response [4]. Further-
more, reliable reports of fulminant MH episodes in
humans or animals induced by administration of SCh
alone are lacking in the current literature [2].
Hence, the aim of the present study was to investigate
the hemodynamic and metabolic response in MH suscep-
tible (MHS) and non-susceptible (MHN) pigs following
application of SCh, halothane or the combination of both
pharmacological agents, to evaluate the influence of SCh
on porcine MH events.Methods
Experimental protocol
With approval of the local animal care committee
(Government of Unterfranken, Wuerzburg, Germany,l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ing 30.6 (27.8 – 31.5) kg were examined. Prior to the
investigation, MH susceptibility or wild type was deter-
mined by DNA analysis regarding the presence of a
homozygous arginine 615 mutation of the ryanodine
receptor indicating MHS.
Anaesthesia was induced intravenously via an ear
vein with thiopental (14 – 17 mg/kg) and maintained
using a midazolam (0.2 - 0.4 mg/kg/h) and fentanyl
(0.01 - 0.04 mg/kg/h) infusion in all swine. After the
trachea was intubated (7.0 mm ID endotracheal tube,
Rüsch, Kernen i.R., Germany) without the use of muscle
relaxants, ventilator settings (Servo 900C, Siemens,
Erlangen, Germany) were adjusted to keep an end-tidal
carbon dioxide partial pressure (PCO2) of 30–35 mmHg
(respiratory rate: 12 – 14/min; tidal volume: 10 – 15 mL/kg;
positive end expiratory pressure: 5 mmHg; 50% oxygen and
50% air). Afterwards, two PCO2 probes (ParaTrend 7+, Dia-
metrics Medical Inc., High Wycombe, Buckinghamshire,
UK) were placed under ultrasound guidance into the left
triceps muscle and into the left femoral vein of the animals.
Vital signs of the animals were monitored continuously
by mean arterial blood pressure (MAP) in the saphenous
artery, peripheral oxygen saturation (SaO2), ECG and
rectal temperature. A warming blanket and an infrared
lamp were used to prevent the animals from hypothermia.
In 15 minutes intervals arterial blood samples were ob-
tained and immediately analysed for pH, arterial oxygen
partial pressure (PaO2), carbon dioxide partial pres-
sure (PaCO2), base excess (BE) and lactate. Through-
out the experiment 4 mL/kg/h Ringer solution (B. Braun,
Melsungen, Germany) was administered via a central
venous line placed in the right jugular vein.
After stable conditions were achieved, animals were
subdivided into three groups. Following baseline record-
ing, the SCh group (MHS: n = 9; MHN: n = 10) received
two single boluses of SCh 4 mg/kg (Nycomed Pharma
GmbH, Unterschleissheim, Germany) at intervals of
15 minutes, while in the halothane group (MHS: n = 6;
MHN: n = 10) the anaesthetic vapor setting was adjusted
to achieve an end-tidal halothane concentration of 0.5 vol%
for the first 15 minutes, followed by an elevation to
1 vol% for further 15 minutes. In a third group (MHS:
n = 12; MHN: n = 10) a single bolus of SCh 4 mg/kg
combined with an end-tidal halothane concentration of
0.5 vol% was applied at first and was augmented after
15 minutes by another SCh bolus 4 mg/kg and an
increase of halothane to 1 vol%. Different sizes of the
investigated groups were caused by the availability of
the animals. Intramuscular and femoral venous PCO2
were recorded in 1-minute intervals. Arterial blood
samples were analysed before and after drug applica-
tion. Systemic hemodynamic parameters were monitored
throughout the experiment. The clinical occurrence ofMH was defined as the development of at least four
out of six conditions: arterial pH ≤ 7.20, PaCO2 ≥
50 mmHg, arterial BE ≤ −5 mmol/l, lactate ≥ 5 mM,
end-tidal PCO2 ≥ 45 mmHg and an increase of rectal
core temperature ≥ 38.5°C [5].
Carbon dioxide measurements
The fiberoptic PCO2 sensor consisted of an optode, kept
in a heparin-coated microporous polyethylene tube of
approximately 0.5 mm in diameter and permeable to the
substance to be measured. The cylindrical sensor con-
struction allowed measurements over the entire probe
surface. Prior to insertion in the target tissue, the probes
were calibrated in vitro by exposure to different standard
gas concentrations (TrendCare Calibrator, Diametrics
Medical Inc., High Wycombe, Buckinghamshire, UK).
Statistical analysis
Data are displayed as median and interquartile range.
Statistical comparisons between and within the investi-
gated groups were performed by repeated measures
ANOVA and post-hoc Tukey test. A value of p < 0.05
was considered statistically significant.
Results
Clinical occurrence of MH
According to the predefined metabolic parameters none
of the MHN swine developed any clinical signs of an
MH episode after application of SCh, halothane or both
agents. In contrast, MH occurred in all MHS animals of
the halothane and the SCh plus halothane group, while
only four out of nine MHS pigs in the SCh group ful-
filled the defined criteria.
Hemodynamic data
Prior to drug application hemodynamic variables and rec-
tal temperature were comparable between the investigated
groups. While in MHN swine SCh had little or no effect
on hemodynamic parameters, relevant hypotension, tachy-
cardia and an increase in end-tidal PCO2 were observed in
all MHS animals. However, SCh did not induce a rise of
body temperature in the MHS pigs.
Interestingly, incremental concentrations of halothane
caused a significant decrease of arterial blood pressure
in both investigated groups, while increases of end-tidal
PCO2 only became significant in MHS swine. But, nei-
ther heart rate nor rectal temperatures were significantly
affected by halothane application in normal or suscep-
tible animals.
In contrast, the effects of halothane combined with
SCh were numerous and pronounced. Beside distinctive
hypotension and tachycardia, a significant temperature
increase was noticed in MHS pigs. Furthermore, changes
in end-tidal PCO2 were significantly different between
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eleven of the twelve MHS pigs immediately died after
reinjection of SCh and raise of end-tidal halothane con-
centration to 1 vol%. Even MHN pigs developed signifi-
cant hypotension and tachycardia after administration
of halothane plus SCh (Table 1).
Metabolic data
Arterial blood gas samples
There were no significant metabolic differences in arter-
ial blood samples prior to SCh, halothane or SCh and
halothane application between MHS and MHN swine.
With exception of minor PaO2 alterations, neither SCh
nor halothane or the combination of both agents re-
sulted in serious changes of metabolic variables in the
MHN groups. However, in MHS animals SCh alone
caused a significant and severe decrease in pH and BE
and a relevant increase of PaCO2 and serum lactate.Table 1 Hemodynamic variables of malignant hyperthermia s
following succinylcholine or halothane or succinylcholine and
Diagnose Time [min| HR [bpm] MAP
MHSSCh (n = 9)
0 min 53 [52–61] 84 [
15 min 58 [53–65] 85 [
30 min 73 [63–85]* 67 [5
45 min 70 [68–92]* 66 [6
MHNSCh (n = 10)
0 min 67 [63–72] 75 [
15 min 71 [63–75] 74 [
30 min 72 [67–75] 72 [
45 min 66 [61–70] 71 [
MHSHalothane (n = 6)
0 min 61 [60–66] 82 [
15 min 58 [55–66] 82 [
30 min 61 [59–64] 49 [4
45 min 76 [61–110] 41 [3
MHNHalothane (n = 10)
0 min 64 [57–70] 72 [
15 min 64 [55–69] 73 [
30 min 68 [61–76] 66 [5
45 min 69 [62–73] 51 [4
MHSHalothane+SCh (n = 12)
0 min 65 [55–87] 60 [
15 min 80 [70–92]* 60 [
30 min 168 [113–204]*# 41 [3
45 min 200+ 6
MHNHalothane+SCh (n = 10)
0 min 71 [61–79] 67 [
15 min 83 [73–97]* 61 [
30 min 93 [84–102]* 57 [5
45 min 100 [95–105]* 52 [4
t = 0 minutes: Baseline values; t = 15 minutes: Application of 4 mg/kg succinylcholin
succinylcholine or 1 vol% halothane or both.
HR = heart rate; MAP =mean arterial blood pressure; SaO2 = peripheral oxygen satu
Data as median and interquartile range;
*significant changes from baseline values; #significant differences between MHS anSystemic halothane aggravated the metabolic alterations
in the MHS group. Furthermore, simultaneous applica-
tion of halothane and SCh resulted in an earlier and
more distinctive metabolic deterioration and was lethal
for the majority of the MHS pigs (Table 2).
Muscular and femoral venous carbon dioxide
measurements
Intramuscular and femoral venous baseline PCO2 levels
before trigger application were comparable between the
investigated MHS and MHN animals. In MHN pigs no
differences in muscular or venous PCO2 values were re-
corded at any experimental time point following SCh
and/or halothane application (Table 3 and Table 4). In
contrast, intravenous SCh and systemic halothane re-
spectively resulted in a significant increase of femoral
venous PCO2 in MHS pigs. In addition, simultaneous
application of SCh and halothane induced an even moreusceptible (MHS) and non-susceptible (MHN) pigs
halothane application
[mmHg] SaO2 [%] etCO2 [mmHg] Temperature [°C]
83–89] 98 [98–98] 35 [31–35] 37,3 [37,1-37,3]
82–89] 98 [97–98] 35 [32–36] 37,2 [37,0-37,3]
5–74]* 98 [97–98] 48 [42–51]*# 37,5 [37,2-37,5]
0–76]* 98 [97–98] 54 [44–62]*# 37,6 [37,3-37,9]
70–86] 99 [97–100] 33 [30–35] 37,0 [36,8-37,5]
67–81] 99 [96–100] 33 [30–35] 36,9 [36,7-37,4]
68–76] 99 [98–100] 34 [31–34] 37,0 [36,6-37,4]
69–76] 99 [97–100] 34 [31–35] 37,0 [36,6-37,4]
75–84] 98 [98–99] 33 [30–35] 37,4 [36,9-37,5]
76–87] 98 [97–99] 33 [30–34] 37,4 [36,9-37,4]
5–53]*# 98 [97–99] 36 [32–40]* 37,3 [37,0-37,5]
8–45]* 97 [95–98] 55 [44–65]* 37,5 [37,1-37,9]
70–79] 98 [98–100] 33 [31–35] 36,8 [36,6-37,3]
68–80] 98 [97–99] 35 [31–35] 37,0 [36,8-37,2]
5–72]* 99 [98–100] 33 [31–34] 37,1 [36,6-37,2]
5–56]* 99 [97–100] 31 [29–33]*# 37,0 [36,8-37,3]
59–72] 98 [98–99] 31 [30–32] 37,5 [37,4-37,9]
55–75] 98 [97–99] 33 [32–34]* 37,5 [37,3-37,8]
5–45]* 96 [95–98]* 63 [55–65]*# 38,0 [37,6-38,2]*#
0+ 98+ 79+ 39,5+
60–80] 99 [97–99] 33 [31–33] 37,6 [37,1-37,8]
60–78] 98 [97–99] 32 [31–34] 37,2 [37,1-37,6]*
3–60]* 98 [96–98] 31 [30–32] 37,0 [36,8-37,5]*
8–60]* 96 [95–100] 32 [30–32] 36,9 [36,7-37,4]*
e or 0.5 vol% halothane or both; t = 30 minutes: Application of 4 mg/kg
ration; etCO2 = end-tidal carbon dioxide; SCh = succinylcholine.
d MHN; p < 0.05. +: data from only one MHS animal.
Table 2 Arterial blood gas samples of malignant hyperthermia susceptible (MHS) and non-susceptible (MHN) pigs
following succinylcholine or halothane or succinylcholine and halothane application
Diagnose Time [min| pH PaO2 [mmHg] PaCO2 [mmHg] BE [mmol/l] Lactate [mM]
MHSSCh (n = 9)
0 min 7,38 [7,36-7,44] 260 [242–285] 40 [38–43] 0,5 [−1,7-1,2] 0,5 [0,4-0,7]
15 min 7,39 [7,37-7,44] 282 [263–298]# 40 [38–42] 0,0 [−1,7-1,2] 0,5 [0,4-0,6]
30 min 7,21 [7,11-7,22]*# 243 [194–269] 59 [55–66]*# −4,6 [−9,2- -3,6]*# 2,7 [2,2,3,2]*#
45 min 7,19 [7,11-7,23]*# 240 [229–255] 64 [57–72]*# −3,7 [−9,2- -3,6]*# 1,5 [1,2-1,8]*#
MHNSCh (n = 10)
0 min 7,42 [7,37-7,45] 246 [187–274] 42 [39–43] 2,0 [−0,2-2,6] 0,7 [0,5-0,9]
15 min 7,42 [7,37-7,43] 249 [197–266] 42 [40–45] 1,8 [−0,4-2,5] 0,6 [0,5-0,7]
30 min 7,40 [7,36-7,44] 233 [183–271] 43 [39–46] 2,7 [0,3-3,0] 0,6 [0,5-1,0]
45 min 7,39 [7,36-7,44] 253 [198–268] 44 [39–46] 1,4 [−0,4-2,4] 0,6 [0,5-0,7]
MHSHalothane (n = 6)
0 min 7,38 [7,34-7,39] 260 [257–270] 40 [39–41] −1,2 [−2,5- -0,4] 0,6 [0,5-0,7]
15 min 7,39 [7,36-7,42] 265 [257–265] 39 [38–40] −0,2 [−1,5-0,4] 0,5 [0,4-0,6]
30 min 7,29 [7,19-7,38] 254 [248–259] 48 [41–52] −3,2 [−8,9- -0,4] 2,4 [1,7-5,1]
45 min 7,03 [6,99-7,09]*# 212 [192–247] 67 [58–77]*# −12,3 [−15,1- -10,8]*# 9,0 [8,2-9,9]*#
MHNHalothane (n = 10)
0 min 7,39 [7,35-7,42] 247 [201–279] 43 [39–46] 0,5 [−1,5-1,1] 0,6 [0,5-0,8]
15 min 7,38 [7,33-7,42] 249 [195–276] 43 [39-46| 0,0 [−1,8-0,9] 0,8 [0,6-1,0]
30 min 7,39 [7,35-7,49] 238 [200–253] 42 [38–46] −0,3 [−2,2-0,8] 0,9 [0,5-1,1]
45 min 7,39 [7,34-7,40] 232 [179–259]* 40 [39–44] −1,0 [−2,6-0,6] 0,6 [0,5-1,0]
MHSHalothane+SCh (n = 12)
0 min 7,47 [7,41-7,51] 256 [250–281] 36 [32–37] 2,4 [0,3-4,6] 1,1 [0,9-1,4]
15 min 7,42 [7,33-7,44]* 261 [247–271] 39 [38–44]* 0,1 [−2,6-2,1] 3,1 [1,6-3,6]
30 min 6,90 [6,83-7,13]*# 256 [194–314]# 69 [33–87]*# −18,6 [−23,3- -15,0]*# 15,7 [15,3-21,4]*#
45 min 6,69+ 247+ 42+ −34,1+ 29,5+
MHNHalothane+SCh (n = 10)
0 min 7,41 [7,41-7,48] 262 [242–291] 36 [35–38] 1,0 [−1,9-3,3] 1,1 [0,9-1,4]
15 min 7,44 [7,37-7,46] 243 [231–274] 37 [36–41] 0,3 [−21-2,8] 1,1 [0,9-1,4]
30 min 7,38 [7,35-7,44] 238 [216–274] 37 [36–38] −0,4 [−3,6-1,5] 1,3 [1,0-1,4]
45 min 7,37 [7,34-7,43] 239 [205–253]* 39 [37–40] −2,3 [−4,7- -0,5] 1,2 [1,1-1,3]
t = 0 minutes: Baseline values; t = 15 minutes: Application of 4 mg/kg succinylcholine or 0.5 Vol% halothane or both; t = 30 minutes: Application of 4 mg/kg
succinylcholine or 1 Vol% halothane or both.
SCh = succinylcholine; PaO2 = arterial oxygen partial pressure; PaCO2 = arterial carbon dioxide partial pressure; BE = base access.
Data as median and interquartile range.
*significant changes from baseline values; #significant differences between MHS and MHN; p < 0.05. +: data from only one MHS animal.
Table 3 Femoral venous carbon dioxide partial pressure (PCO2) of malignant hyperthermia susceptible (MHS) and
non-susceptible (MHN) pigs following succinylcholine or halothane or succinylcholine and halothane application
Diagnose Femoral venous PCO2 [mmHg] t = 0 min t = 15 min t = 30 min t = 45 min
MHSSCh (n = 9) 51 [45–54] 52 49–56] 78 [67–93]*
# 79 [72–105]*#
MHNSCh (n = 10) 50 [43–55] 49 [44–54] 51 [45–56] 49 [43–56]
MHSHalothane (n = 6) 59 [46–67] 55 [45–60] 71 [58–84]* 138 [98–152]*
#
MHNHalothane (n = 10) 50 [44–58] 52 [44–57] 54 [44–58] 54 [44–60]
MHSHalothane+SCh (n = 12) 51 [47–56] 57 [53–64] 151 [110–192]*
# 199+
MHNHalothane+SCh (n = 10) 51 [44–53] 49 [44–52] 50 [47–57] 51 [47–61]
t = 0 minutes: Baseline values; t = 15 minutes: Application of 4 mg/kg succinylcholine or 0.5 vol% halothane or both; t = 30 minutes: Application of 4 mg/kg
succinylcholine or 1 vol% halothane or both.
SCh = succinylcholine.
Data as median and interquartile range.
*significant changes from baseline values; #significant differences between MHS and MHN; p < 0.05. +: data from only one MHS animal.
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Table 4 Muscular carbon dioxide partial pressure (PCO2) of malignant hyperthermia susceptible (MHS) and
non-susceptible (MHN) pigs following succinylcholine or halothane or succinylcholine and halothane application
Diagnose Muscular PCO2 [mmHg] t = 0 min t = 15 min t = 30 min t = 45 min
MHSSCh (n = 9) 60 [45–64] 59 [45–62] 73 [65–87]*
# 78 [69–92]*#
MHNSCh (n = 10) 54 [41–59] 55 [46–60] 56 [47–59] 58 [50–60]
MHSHalothane (n = 6) 54 [51–58] 54 [50–57] 59 [57–71] 106 [101–120]*
#
MHNHalothane (n = 10) 59 [48–63] 58 [49–62] 54 [48–63] 56 [48–60]
MHSHalothane+SCh (n = 12) 56 [48–60] 56 [47–66] 114 [56–167] 140+
MHNHalothane+SCh (n = 10) 56 [54–65] 56 [47–66] 56 [55–65] 58 [56–68]
t = 0 minutes: Baseline values; t = 15 minutes: Application of 4 mg/kg succinylcholine or 0.5 vol% halothane or both; t = 30 minutes: Application of 4 mg/kg
succinylcholine or 1 vol% halothane or both.
SCh = succinylcholine.
Data as median and interquartile range;
*significant changes from baseline values; #significant differences between MHS and MHN; p < 0.05. +: data from only one MHS animal.
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The changes of muscular PCO2 values were similar to
the femoral venous results. SCh induced a significant,
but compared to halothane a minor increase of muscular
PCO2. Simultaneous exposure of MHS pigs to SCh and
halothane aggravated the changes of muscular metabolism
(Table 4).
Noteworthy, in MHS animals application of halothane
and/or SCh resulted in a more distinctive and rapid in-
crease of PCO2 in the triceps muscle and in the femoral
venous blood compared to PaCO2 and end-tidal PCO2
values. (Table 2, Table 3 and Table 4).
Discussion
The disturbance of intracellular calcium homeostasis
due to an uncontrolled sarcoplasmic calcium release via
mutated calcium releasing channels is widely accepted
as the underlying pathophysiological mechanism of MH.
The excessive increase of skeletal muscular intracellular
calcium levels in MHS individuals leads to muscle rigidity,
enhanced mitochondrial energy turnover with excessive
oxygen consumption, carbon dioxide increase, heat pro-
duction and metabolic acidosis [1,6].
Undoubtedly, all volatile anaesthetics have the ability
to provoke an MH episode [2]. For instance, it is well
known that halothane induces an excessive sarcoplasmic
calcium release in predisposed individuals via interaction
with altered ryanodine receptors subtype 1, leading to the
clinical syndrome of MH [7,8]. The hemodynamic and
above all the metabolic changes observed in this inves-
tigation with decrease of pH and BE combined with sig-
nificant increases of end-tidal PCO2, PaCO2 and lactate
following halothane exposition in MHS swine docu-
mented once again the MH inducing potency of volatiles.
In contrast, the underlying mode of action or the
impact of SCh to elicit an MH remained unclear so far.
Larach and colleagues rated 284 cases that were suspicious
of MH and had been reported to the North American
MH Registry using a clinical grading scale to evaluatethe likelihood of truly being MH. Only two cases (0.7%)
were regarded as ”very likely“ or ”almost certain“ being
MH, after SCh had been applied to the patients but not
a volatile anaesthetic [9]. Recently, a European multi-
centre study analysed the cases of 200 patients with
history of a clinical MH episode and confirmed MH
disposition by in vitro contracture test. In this study
only two patients (1%; 1 MHS and 1 MH equivocal) with
SCh induced MH crisis in absence of any inhalation an-
aesthetic were identified [10].
In animals, intramuscular injection of halothane resulted
in a local hypermetabolic response with locally limited rise
of lactate and PCO2, enabling a differentiation between
MH susceptible and normal pigs [11], while local SCh
did not initiate a metabolic reaction [12]. Furthermore,
variable responses to intravenous SCh application were
reported in susceptible swine. While in previous studies
an MH episode could not be elicited with SCh alone
[13,14], Iaizzo and colleagues demonstrated that SCh
induced porcine MH [15,16]. However, the fact that
acidosis and hypercapnia occurred shortly after SCh-
induced hypotension and tachycardia, which were treated
with intravenous saline infusion does not exclude reperfu-
sion of temporary hypoperfused tissue to be causal for the
metabolic alterations [15]. In contrast to this previous
study, in the presented investigation the decrease of arter-
ial blood pressure induced by SCh was not treated. Hence,
the observed metabolic reactions, including a decrease of
pH and BE and an increase of end-tidal PCO2, PaCO2 and
lactate as well as muscular and femoral PCO2 in suscep-
tible pigs, are likely to be signs of a developing MH. Even
if the alterations after SCh were less distinctive compared
to the halothane-induced effects, our results documented
a severe metabolic stimulation in the susceptible animals.
Possible explanations for SCh-induced MH may be
based on the pharmacological characteristics of this agent.
After intravenous injection, SCh activates the nicotinergic
acetylcholine receptor, which acts as an unspecific cat-
ion channel provoking a local depolarization of the cell
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receptors and an influx of extracellular calcium via the
nicotinergic acetylcholine receptors followed by an in-
crease of intracellular calcium levels may trigger MH in
predisposed individuals [17]. In this context, muscular
fasciculation and rigidity caused by SCh were considered
to be causal for MH, since pre-treatment with non-
depolarizing muscle relaxants diminished or completely
prevented the appearance of an MH episode [15,16,18].
Thereby, the rise of intracellular calcium during the
depolarisation period itself might be sufficient to initiate
sarcoplasmic calcium release and after exceeding individ-
ual thresholds, MH occurs in affected individuals. Similar
to previous studies prolonged fasciculation was seen in the
investigated MHS pigs. However, the importance and the
exact mode of action of SCh in setting off an MH episode
are still indistinct and require further research.
In the current study, simultaneous application of
halothane and succinylcholine potentiated the induced
hemodynamic and metabolic effects compared to the
changes following administration of halothane or SCh
alone in MHS swine. Interestingly, a significant rise of
body temperature only occurred after administration of a
combination of both pharmacological agents, reflecting
the severe metabolic breakdown. Our findings suggest an
additive effect of SCh as postulated by previous investiga-
tions in which the onset of an MH episode was signifi-
cantly enhanced and the increase of serum creatine kinase
was more pronounced after a combination of SCh and
volatile anaesthetics [10,19,20].
Hypermetabolism during a fulminant MH episode is
typically associated with an excessive increase of end-
tidal and arterial carbon dioxide concentrations [1,6].
The more distinctive rise of femoral venous and muscu-
lar PCO2 levels compared to PaCO2 and end-tidal PCO2
in MHS swine might be caused by a significant muscular
venous outflow of carbon dioxide. Hence, blood gas ana-
lysis of venous blood might be as helpful as an arterial
blood gas in clinical practice for real time detection of a
developing MH episode.
Conclusions
In conclusion, the findings of our investigation clearly
demonstrated, that both SCh and halothane alone had the
ability to induce an MH in susceptible swine. Further-
more, the observed hemodynamic and metabolic effects
were excessively potentiated by combination of both
pharmacological agents. Based on these results, SCh
acts independent as well as supportive to provoke an
MH episode in predisposed individuals. Hence, even if
convincing reports of fulminant MH in humans induced
by SCh alone are lacking, the obtained findings of our
study proved the MH eliciting potency of SCh. However,
the underlying mode of action of SCh to cause an MHepisode still remains unclear and needs to be evaluated in
further investigations.
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